Aflibercept reduces subfoveal fluid in eyes with persistent exudative AMD

Aflibercept yielded positive anatomic results in cases of exudative age-related macular degeneration that were resistant to ranibizumab or bevacizumab, according to a study.“Visual acuity did not improve. Aflibercept may be beneficial anatomically in cases of exudative AMD treated with persistent fluid on ranibizumab and/or bevacizumab,” the study authors said.

Full Story →